Trial of the Combination of Alpha-Lipoic Acid and Mirabegron in Women and in Men With Obesity

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 28, 2025

Primary Completion Date

March 1, 2026

Study Completion Date

March 1, 2026

Conditions

Insulin ResistanceObesity

Interventions

DRUG

Placebo

DRUG

Mirabegron

selective beta3-AR agonist approved

DRUG

Alpha-lipoic acid

ALA is an antioxidant that is available over the counter

Trial Locations (1)

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors

lead

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH